CN102143748A - 用于肺结核的联合疗法 - Google Patents

用于肺结核的联合疗法 Download PDF

Info

Publication number
CN102143748A
CN102143748A CN200980134310XA CN200980134310A CN102143748A CN 102143748 A CN102143748 A CN 102143748A CN 200980134310X A CN200980134310X A CN 200980134310XA CN 200980134310 A CN200980134310 A CN 200980134310A CN 102143748 A CN102143748 A CN 102143748A
Authority
CN
China
Prior art keywords
formula
compound
tuberculosis
treatment
rifampicin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980134310XA
Other languages
English (en)
Chinese (zh)
Inventor
S·J·布里克纳
E·纽尔姆伯格
C·K·斯托沃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Johns Hopkins University
Original Assignee
Pfizer Corp SRL
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41279484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102143748(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Corp SRL, Johns Hopkins University filed Critical Pfizer Corp SRL
Publication of CN102143748A publication Critical patent/CN102143748A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200980134310XA 2008-09-03 2009-08-31 用于肺结核的联合疗法 Pending CN102143748A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9387908P 2008-09-03 2008-09-03
US61/093,879 2008-09-03
PCT/IB2009/053796 WO2010026526A1 (en) 2008-09-03 2009-08-31 Combination therapy for tuberculosis

Publications (1)

Publication Number Publication Date
CN102143748A true CN102143748A (zh) 2011-08-03

Family

ID=41279484

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980134310XA Pending CN102143748A (zh) 2008-09-03 2009-08-31 用于肺结核的联合疗法

Country Status (14)

Country Link
US (3) US20110190199A1 (enExample)
EP (1) EP2340022B1 (enExample)
JP (1) JP5661037B2 (enExample)
KR (1) KR101318189B1 (enExample)
CN (1) CN102143748A (enExample)
AU (1) AU2009288820A1 (enExample)
BR (1) BRPI0918802A2 (enExample)
CA (1) CA2735229C (enExample)
IL (1) IL211293A (enExample)
MX (1) MX2011002348A (enExample)
NZ (1) NZ591169A (enExample)
RU (1) RU2484819C2 (enExample)
WO (1) WO2010026526A1 (enExample)
ZA (1) ZA201101742B (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102786516A (zh) * 2012-08-21 2012-11-21 湖南师范大学 一种利伐沙班的合成方法
CN105853461A (zh) * 2016-06-14 2016-08-17 黄峰 一种治疗肺结核的药物组合
CN106581048A (zh) * 2016-12-07 2017-04-26 郑州郑先医药科技有限公司 一种治疗肺结核的西药组合及其制备方法
CN106580915A (zh) * 2016-10-13 2017-04-26 中国人民解放军第三〇九医院 一种载利福喷丁和利奈唑胺的缓释微球及其制备方法和用途
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
CN107243008A (zh) * 2017-04-13 2017-10-13 中国科学院广州生物医药与健康研究院 吡唑并[1,5‑a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN108472292A (zh) * 2015-10-29 2018-08-31 奥斯瓦道·克鲁兹基金会 药物组合物、固定剂量的甲氟喹的用途和用于治疗结核病的方法
CN109223778A (zh) * 2018-11-16 2019-01-18 上海市肺科医院 C24h24n6o2s3在制备抗结核菌药物中的用途
CN113730550A (zh) * 2021-04-06 2021-12-03 中国医学科学院医药生物技术研究所 博宁霉素在治疗耐药性结核病中的应用
CN114354804A (zh) * 2021-12-31 2022-04-15 深圳市第三人民医院(深圳市肝病研究所) 试剂盒和样本中抗结核药物及其代谢物的检测方法
CN114796231A (zh) * 2015-10-14 2022-07-29 结核病药物开发全球联盟公司 联合抗菌组合物以及短疗程抗菌方案
CN115605208A (zh) * 2020-03-20 2023-01-13 默沙东有限责任公司（Us） 噁唑烷酮化合物及其作为抗菌剂的使用方法
CN117045657A (zh) * 2022-05-12 2023-11-14 广州嘉越医药科技有限公司 一种药物组合及其应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2464016C2 (ru) * 2010-06-11 2012-10-20 Ольга Германовна Челнокова Способ лечения туберкулеза
ES2395304B1 (es) * 2011-05-20 2014-01-16 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.
CN103869040B (zh) * 2012-12-14 2016-12-28 上海科胜药物研发有限公司 一种特立齐酮中d‑环丝氨酸含量的测定分析方法
WO2015126922A2 (en) * 2014-02-18 2015-08-27 Stc. Unm Rapid phenotype tests for antitubercular drug sensitivity and resistance
EA201700155A1 (ru) * 2014-10-20 2017-10-31 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтическая композиция для лечения туберкулеза
US10080749B2 (en) * 2014-11-03 2018-09-25 The Regents Of The University Of California Multi-drug therapies for tuberculosis treatment
HRP20230616T1 (hr) * 2015-01-27 2023-09-29 Janssen Pharmaceutica Nv Disperzivni pripravci
RU2627611C2 (ru) * 2015-10-30 2017-08-09 Акционерное общество "Фармасинтез" (АО "Фармасинтез") Противотуберкулезная фармацевтическая композиция, содержащая тиоацетазон
WO2017120529A1 (en) 2016-01-08 2017-07-13 Institute For Systems Biology Methods to identify antituberculosis compounds
RU2650633C2 (ru) * 2016-06-02 2018-04-16 Государственное бюджетное учреждение Республики Саха (Якутия) "Научно-практический центр "Фтизиатрия" Способ лечения инфильтративного туберкулеза легких с множественной лекарственной устойчивостью
WO2018190680A1 (ko) * 2017-04-13 2018-10-18 충남대학교산학협력단 세포내 결핵균 제어를 위한 뉴트린-3α 및 피53 발현 조절 조성물 또는 방법
KR102082285B1 (ko) * 2017-04-13 2020-02-28 충남대학교산학협력단 세포내 결핵균 제어를 위한 Nutlin-3α (뉴트린-3α) 및 p53 발현 조절 조성물 또는 방법
WO2018191628A1 (en) * 2017-04-14 2018-10-18 The Regents Of The University Of California Multi-drug therapies for tuberculosis treatment
RU2702607C1 (ru) * 2018-07-25 2019-10-08 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИТ" Минздрава России) Способ лечения туберкулеза мочевого пузыря
CN110441434A (zh) * 2019-08-29 2019-11-12 重庆华邦胜凯制药有限公司 Gc-ms分离测定对氨基水杨酸中相关杂质的方法
WO2021188834A1 (en) * 2020-03-18 2021-09-23 The Board Of Trustees Of The Leland Stanford Junior University Detection of gene polymorphisms
WO2021257466A1 (en) * 2020-06-15 2021-12-23 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and method for antibacterial therapy
WO2021257461A1 (en) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Combination antibacterial composition and method for antibacterial therapy
EP4271679A4 (en) * 2021-02-01 2024-09-11 The Global Alliance for TB Drug Development, Inc. AMORPHOUS FORM OF PRETOMANIDES
WO2024035618A1 (en) * 2022-08-10 2024-02-15 Merck Sharp & Dohme Llc Processes for preparing oxazolidinone compounds
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
CN120004814B (zh) * 2025-02-13 2025-08-12 山西立业制药有限公司 一种氯法齐明乙醇晶型化合物及其制备方法和应用、药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880118A (en) * 1993-09-09 1999-03-09 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009025820A2 (en) * 2007-08-21 2009-02-26 Stc. Unm Rationally improved isoniazid and ethionamide derivatives and activity through selective isotopic substitution

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880118A (en) * 1993-09-09 1999-03-09 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALLELL L ET AL: "New Small-Molecule Synthetic Antimycobacterials", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
CYNAMON M H ET AL: "Activities of Several Novel Oxazolidinones against Mycobacterium tuberculosis in a Murine Model", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102786516A (zh) * 2012-08-21 2012-11-21 湖南师范大学 一种利伐沙班的合成方法
CN102786516B (zh) * 2012-08-21 2014-10-01 湖南师范大学 一种利伐沙班的合成方法
CN114796231A (zh) * 2015-10-14 2022-07-29 结核病药物开发全球联盟公司 联合抗菌组合物以及短疗程抗菌方案
US10947205B2 (en) 2015-10-22 2021-03-16 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
CN108472292B (zh) * 2015-10-29 2021-08-10 奥斯瓦道·克鲁兹基金会 药物组合物、固定剂量的甲氟喹的用途和用于治疗结核病的方法
CN108472292A (zh) * 2015-10-29 2018-08-31 奥斯瓦道·克鲁兹基金会 药物组合物、固定剂量的甲氟喹的用途和用于治疗结核病的方法
CN105853461A (zh) * 2016-06-14 2016-08-17 黄峰 一种治疗肺结核的药物组合
CN106580915A (zh) * 2016-10-13 2017-04-26 中国人民解放军第三〇九医院 一种载利福喷丁和利奈唑胺的缓释微球及其制备方法和用途
CN106580915B (zh) * 2016-10-13 2019-11-08 中国人民解放军第三〇九医院 一种载利福喷丁和利奈唑胺的缓释微球及其制备方法和用途
CN106581048A (zh) * 2016-12-07 2017-04-26 郑州郑先医药科技有限公司 一种治疗肺结核的西药组合及其制备方法
CN107243008A (zh) * 2017-04-13 2017-10-13 中国科学院广州生物医药与健康研究院 吡唑并[1,5‑a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN109223778A (zh) * 2018-11-16 2019-01-18 上海市肺科医院 C24h24n6o2s3在制备抗结核菌药物中的用途
CN109223778B (zh) * 2018-11-16 2021-07-27 上海市肺科医院 C24h24n6o2s3在制备抗结核菌药物中的用途
CN115605208A (zh) * 2020-03-20 2023-01-13 默沙东有限责任公司（Us） 噁唑烷酮化合物及其作为抗菌剂的使用方法
US12435077B2 (en) 2020-03-20 2025-10-07 Merck Sharp & Dohme Llc Oxazolidinone compound and methods of use thereof as an antibacterial agent
CN113730550A (zh) * 2021-04-06 2021-12-03 中国医学科学院医药生物技术研究所 博宁霉素在治疗耐药性结核病中的应用
CN113730550B (zh) * 2021-04-06 2023-08-18 中国医学科学院医药生物技术研究所 博宁霉素在治疗耐药性结核病中的应用
CN114354804A (zh) * 2021-12-31 2022-04-15 深圳市第三人民医院(深圳市肝病研究所) 试剂盒和样本中抗结核药物及其代谢物的检测方法
CN117045657A (zh) * 2022-05-12 2023-11-14 广州嘉越医药科技有限公司 一种药物组合及其应用
WO2023217239A1 (zh) * 2022-05-12 2023-11-16 广州嘉越医药科技有限公司 一种药物组合及其应用

Also Published As

Publication number Publication date
RU2484819C2 (ru) 2013-06-20
IL211293A0 (en) 2011-04-28
ZA201101742B (en) 2011-11-30
NZ591169A (en) 2012-12-21
IL211293A (en) 2016-08-31
CA2735229C (en) 2014-01-28
JP2012502017A (ja) 2012-01-26
AU2009288820A1 (en) 2010-03-11
KR20110063518A (ko) 2011-06-10
WO2010026526A1 (en) 2010-03-11
EP2340022A1 (en) 2011-07-06
EP2340022B1 (en) 2013-11-20
US20170368070A1 (en) 2017-12-28
KR101318189B1 (ko) 2013-10-16
CA2735229A1 (en) 2010-03-11
MX2011002348A (es) 2011-06-27
US20160220578A1 (en) 2016-08-04
US20110190199A1 (en) 2011-08-04
BRPI0918802A2 (pt) 2019-09-17
JP5661037B2 (ja) 2015-01-28
RU2011108026A (ru) 2012-10-10

Similar Documents

Publication Publication Date Title
CN102143748A (zh) 用于肺结核的联合疗法
US9284325B2 (en) Spectinamides as anti-tuberculosis agents
CA2842508C (en) Bis-indolic derivatives, their uses in particular as antibacterials
KR20250026145A (ko) 비결핵성 마이코박테리움 감염 치료에서의 붕소 화합물의 방법 및 용도 및 상기 감염의 치료를 위한 제약 조성물
US10752621B2 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
US10702575B2 (en) Pharmaceutical composition for preventing or treating mycobacterium species infection and method using the same
CN106660990B (zh) 新型氟喹诺酮和其用于治疗细菌感染的用途
HK1155971A (en) Combination therapy for tuberculosis
CN115551499A (zh) 一种含有大环内酯类化合物的药物组合物、其制备方法和将其使用的方法
CN117858708A (zh) F-atp合酶抑制剂用于治疗脓肿分枝杆菌疾病的发现
WO2010122456A1 (en) Compositions of sulopenem and use for treating tuberculosis
JP2003160480A (ja) Ｎｋ１受容体拮抗薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1155971

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110803

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1155971

Country of ref document: HK